Saturday, December 06, 2025 | 02:59 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Moderna, Pfizer Covid-19 vaccines look strong: Here's how they stack up

The data will likely increase confidence that more vaccines will work and that the world may soon find a way to get the coronavirus under control

moderna, covid, vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
premium

In this July 27, 2020, file photo, a nurse prepares a shot that is part of a possible Covid-19 vaccine, developed by the National Institutes of Health and Moderna Inc., in Binghamton, N.Y. (AP Photo/Hans Pennink, File)

James Paton | Bloomberg
The first two Covid-19 vaccines out of the gate have now delivered positive news in the quest to end the pandemic. The encouraging late-stage trial results from Pfizer Inc. and Moderna Inc. set a high bar for rivals such as AstraZeneca Plc that are expected to follow soon with their own pivotal reports.
 
The data will likely increase confidence that more vaccines will work and that the world may soon find a way to get the coronavirus under control. Here’s what we know about the two shots.

How do the results compare?

Moderna said Monday its vaccine was 94.5% effective